GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HCW Biologics Inc (NAS:HCWB) » Definitions » EV-to-EBIT

HCW Biologics (HCW Biologics) EV-to-EBIT : -2.41 (As of Apr. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is HCW Biologics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, HCW Biologics's Enterprise Value is $59.44 Mil. HCW Biologics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-24.71 Mil. Therefore, HCW Biologics's EV-to-EBIT for today is -2.41.

The historical rank and industry rank for HCW Biologics's EV-to-EBIT or its related term are showing as below:

HCWB' s EV-to-EBIT Range Over the Past 10 Years
Min: -30.07   Med: -3.4   Max: -1.25
Current: -2.41

During the past 5 years, the highest EV-to-EBIT of HCW Biologics was -1.25. The lowest was -30.07. And the median was -3.40.

HCWB's EV-to-EBIT is ranked worse than
100% of 444 companies
in the Biotechnology industry
Industry Median: 8.05 vs HCWB: -2.41

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. HCW Biologics's Enterprise Value for the quarter that ended in Dec. 2023 was $46.84 Mil. HCW Biologics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-24.71 Mil. HCW Biologics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -52.76%.


HCW Biologics EV-to-EBIT Historical Data

The historical data trend for HCW Biologics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HCW Biologics EV-to-EBIT Chart

HCW Biologics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -3.60 -2.91 -1.90

HCW Biologics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.91 -1.61 -3.64 -3.27 -1.90

Competitive Comparison of HCW Biologics's EV-to-EBIT

For the Biotechnology subindustry, HCW Biologics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HCW Biologics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HCW Biologics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where HCW Biologics's EV-to-EBIT falls into.



HCW Biologics EV-to-EBIT Calculation

HCW Biologics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=59.444/-24.711
=-2.41

HCW Biologics's current Enterprise Value is $59.44 Mil.
HCW Biologics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HCW Biologics  (NAS:HCWB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

HCW Biologics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-24.711/46.8397475
=-52.76 %

HCW Biologics's Enterprise Value for the quarter that ended in Dec. 2023 was $46.84 Mil.
HCW Biologics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HCW Biologics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of HCW Biologics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


HCW Biologics (HCW Biologics) Business Description

Traded in Other Exchanges
N/A
Address
2929 N Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company believes age-related low-grade chronic inflammation is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases.
Executives
Gary M Winer director C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Hing C Wong director, officer: Chief Executive Officer C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rebecca Byam officer: Chief Financial Officer C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lee Flowers officer: SVP of Business Development C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rick S. Greene director C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Jin-an Jiao officer: VP of Development C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Scott T Garrett director 35 CROSBY DRIVE, BEDFORD MA 01730
Peter Rhode officer: See Remarks C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Medmira Capital Ltd. 10 percent owner 16F BEIKE BUILDING, 59 GAOXIN NANJIU RD, SHENZHEN F4 518057

HCW Biologics (HCW Biologics) Headlines

From GuruFocus

HCW Biologics Poster Presentation at AACR Annual Meeting 2023

By sperokesalga sperokesalga 04-13-2023